38 completed, 5 recruiting, 4 unknown, 2 not yet recruiting. 51 Phase 1, 20 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 51 | Completed 38, Recruiting 5, Unknown 4, Not yet recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 20 | Completed 16, Unknown 2, Not yet recruiting 1, Recruiting 1 |
Follow Impulsive Behavior: new trials by email Literature Review of Impulsive Behavior trials Research Report on Impulsive Behavior
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lemborexant for Cannabis Use Disorder Lemborexant 10mg, Placebo, Brief Behavioural Intervention - Cannabis Use Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Calgary | 28 | 2026-11-01 | 2026-09-22 |
| VK4-116 Phase I Study With Food-Effect VK4-116, Placebo - Opioid Dependence, Opioid Use Disorder (OUD) | Phase 1 | Not yet recruiting | National Institute on Drug Abuse (NIDA) | 48 | 2026-08-01 | 2026-04-09 |
| Comparative Evaluation of Nicotine Analogs Biospecimen Collection, Nicotine, 6-Methyl Nicotine - Tobacco-Related Carcinoma, Addiction | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 70 | 2026-05-29 | 2026-06-26 |
| Nalmefene Implant in Healthy Subjects 1 Nalmefene implant, 2 Nalmefene implants - Opioid Abuse and Addiction | Phase 1 | Recruiting | ReacX Pharmaceuticals, Inc. | 24 | 2026-02-23 | 2026-04-06 |
| Ketamine for Combined Depression and Alcohol Use Disorder Ketamine Hydrochloride, Midazolam Hydrochloride - Depression, Alcohol Use Disorder | Phase 1 / Phase 2 | Recruiting | University Hospital of North Norway | 34 | 2025-01-20 | 2026-06-23 |
| Open-Label Psilocybin Study in Transdiagnostic Population Psilocybin - Transdiagnostic, Depression - Major Depressive Disorder | Phase 1 | Recruiting | Yale University | 50 | 2024-10-17 | 2026-03-11 |
| Frontal iTBS for Impulsivity and Suicidal Ideation in Veterans With Mild Traumatic Brain Injury intermittent theta burst stimulation, placebo intermittent theta burst stimulation - Mild Traumatic Brain Injury, Suicidal Ideation | Phase 1 | Recruiting | VA Office of Research and Development | 55 | 2024-05-20 | 2026-04-14 |
| Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Placebo, Auvelity - Addiction, Opioid Use | Phase 1 / Phase 2 | Completed | Virginia Commonwealth University | 18 | 2023-09-18 | 2026-08-19 |
| Boost Study 31380 (mHealth) mHealth - Addiction | Phase 1 | Completed | NXTech | 43 | 2022-04-18 | 2024-12-18 |
| Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160) Combination Product: Naltrexone - Opiod Use Disorder | Phase 1 | Completed | Delpor, Inc. | 10 | 2022-03-22 | 2025-02-13 |
| A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers 18-MC Compound - Addiction | Phase 1 | Completed | Definium Therapeutics US, Inc. | 108 | 2020-04-14 | 2022-01-05 |
| The Effect of Chronic Pain on Delay Discounting in Methadone Patients Naloxone Hydrochloride, Placebo - Opioid-use Disorder, Chronic Pain Syndrome | Phase 1 | Terminated | University of California, San Francisco | 10 | 2020-01-08 | 2025-03-26 |
| Social Decision Making in Parkinson's Disease Pramipexole, Placebo - Parkinson Disease | Phase 1 | Completed | Vanderbilt University Medical Center | 18 | 2019-12-03 | 2023-10-18 |
| Effects of Random Nicotine Delivery on Smoking Cessation Nicotine Film - Smoking Cessation, Cigarette Smoking | Phase 1 / Phase 2 | Completed | Milton S. Hershey Medical Center | 45 | 2019-03-12 | 2021-01-22 |
| The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers ANS-6637 - Opiod Use Disorder | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 26 | 2019-03-01 | 2020-08-03 |
| Effects of Nicotine in Tobacco Smokers Cigarette 1, Cigarette 2, Patch 1 - Smoking, Tobacco, Smoking (Tobacco) Addiction | Phase 1 | Completed | University of Southern California | 221 | 2019-02-04 | 2023-07-13 |
| Use of Intranasal Oxytocin During Detoxification of Crack Cocaine Oxytocin nasal spray, placebo nasal spray, Conventional Inpatient Treatment - Cocaine Withdrawal, Cocaine Smoking | Phase 1 / Phase 2 | Completed | Pontificia Universidade Católica do Rio Grande do Sul | 84 | 2018-09-17 | 2026-09-28 |
| Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants, Placebo - Attention Deficit Hyperactivity Disorder | Phase 1 / Phase 2 | Completed | Oregon Health and Science University | 135 | 2018-04-23 | 2023-02-08 |
| Oxytocin HIV Meth Study Oxytocin, Placebo - Amphetamine Use Disorders | Phase 1 | Completed | University of California, San Francisco | 48 | 2017-01-01 | 2019-03-05 |
| Oxytocin in Alcohol Use Disorder Oxytocin, Placebo - Alcoholism | Phase 1 | Withdrawn | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 2016-03-08 | 2019-04-11 |
Showing 20 of 51. Sign in to see all of them.
Behavior, Addictive (42) · Substance-Related Disorders (17) · Opioid-Related Disorders (10) · Cocaine-Related Disorders (7) · Alcoholism (5) · Depression (4) · Marijuana Abuse (3) · Smoking (3) · Anxiety Disorders (2) · Mental Disorders (2) · Obesity (2) · Pain (2) · Stress Disorders, Post-Traumatic (2) · Suicide (2)
Behavior (50) · Compulsive Behavior (43) · Mental Disorders (38) · Chemically-Induced Disorders (36) · Substance-Related Disorders (19) · Narcotic-Related Disorders (10) · Pathological Conditions, Signs and Symptoms (7) · Behavioral Symptoms (6) · Alcohol-Related Disorders (5) · Signs and Symptoms (5) · Nervous System Diseases (4) · Neurologic Manifestations (4) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3)
Buprenorphine (3) · Cognitive Behavioral Therapy (3) · Oxytocin (3) · Buprenorphine, Naloxone Drug Combination (2) · Cocaine (2) · N-((3,5-difluoro-3'-(1H-1,2,4-triazol-3-yl)-4-biphenylyl)methyl)-2,3-dihydro-1H-inden-2-amine (2) · Transcranial Direct Current Stimulation (2) · 18-methoxycoronaridine (1) · ANS-6637 (1) · Acamprosate (1) · Amino Acids (1) · Amphetamine (1) · Antioxidants (1) · Aprepitant (1) · Atomoxetine Hydrochloride (1)
GlaxoSmithKline (5) · Yale University (4) · University of California, San Francisco (3) · Johns Hopkins University (2) · National Institute on Drug Abuse (NIDA) (2) · Vanderbilt University Medical Center (2) · Virginia Commonwealth University (2) · Baylor College of Medicine (1) · BeerYaakov Mental Health Center (1) · Dartmouth-Hitchcock Medical Center (1) · Definium Therapeutics US, Inc. (1) · Delpor, Inc. (1) · Federal University of Espirito Santo (1) · George Mason University (1) · Jazz Pharmaceuticals (1)
United States (34) · United Kingdom (4) · Australia (3) · Canada (3) · Brazil (2) · Israel (2) · Norway (1) · Sweden (1)
Aaron T. Beck, MD (1) · Abraham Zangen, Ph.D. (1) · Adam M Leventhal, PhD (1) · Ahmed Elkashef, M.D. (1) · Alex Choo, MD (1) · Alexandra L Aaronson, MD (1) · Alexis Vien, MD (1) · Alison Oliveto, PhD (1) · Andreas W Blomkvist, M.D. (1) · Annie Umbricht, M.D. (1) · Benjamin Kelmendi, MD (1) · Brian Smith, MBBS, PhD (1) · Bryan K. Tolliver, M.D., Ph.D. (1) · Chris Stauffer, MD (1)
PMID 21671456, PMID 23144826, PMID 24139147, PMID 24647726, PMID 25414797, PMID 30791944, PMID 31304887, PMID 31763491, PMID 33884617, PMID 34303786, PMID 34697392, PMID 35770861, PMID 38551365, PMID 39671573, PMID 40772654, PMID 41776068
2023 (1), 5UG1DA050207 (1), K01DA027750 (1), K23DA016574 (1), K23DA029609 (1), K24DA000435 (1), P20MH071905 (1), P50DA009262 (1), P50DA027841 (1), R01DA025764 (1), R01DA027065 (1), R21DA020583 (1), R21DA038775 (1), R21DA047520 (1), R25MH071584 (1)